Serum proteomic profiling of major depressive disorder
نویسندگان
چکیده
منابع مشابه
Serum Proteomic Profiling of Obsessive-Compulsive Disorder, Washing Subtype: A Preliminary Study
Introduction: Obsessive-Compulsive Disorder (OCD) is a disabling mental condition that its proteomic profiling is not yet investigated. Proteomics is a valuable tool to discover biomarker approaches. It can be helpful to detect protein expression changes in complex disorders such as OCD. Methods: Here, by the application of 2D gel electrophoresis (2DE), a pilot study of serum proteome profile ...
متن کاملProteomic Analysis of Serum from Patients with Major Depressive Disorder to Compare Their Depressive and Remission Statuses
OBJECTIVE Currently, there are a few biological markers to aid in the diagnosis and treatment of depression. However, it is not sufficient for diagnosis. We attempted to identify differentially expressed proteins during depressive moods as putative diagnostic biomarkers by using quantitative proteomic analysis of serum. METHODS Blood samples were collected twice from five patients with major ...
متن کاملSheehan’s Syndrome Presenting as Major Depressive Disorder
Sheehan’s syndrome or Simmond’s disease is a rare endocrine disorder seen in clinical practice. The clinical spectrum is diverse and a high index of suspicion together with a good clinical acumen and proper diagnostic approach helps in early diagnosis and prompt treatment of this endocrinopathy. Sheehan’s syndrome presenting as a major depressive disorder finds less mention in the literature.Th...
متن کاملIdentifying Early Maladaptive Schema of Patients with Major Depressive Disorder
Cognitive models of depression propose that negative schemas and Early Maladaptive Schema contribute to depressive symptoms. The purpose of this study is to identify the early maladaptive Schema of patients with depression disorder. The method of study is descriptive. Research statistics involves all patients with depression disorder who have come to the c...
متن کاملVortioxetine versus placebo for treatment of major depressive disorder
Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Psychiatry
سال: 2015
ISSN: 2158-3188
DOI: 10.1038/tp.2015.88